GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (MEX:SMMT) » Definitions » Cyclically Adjusted PB Ratio

Summit Therapeutics (MEX:SMMT) Cyclically Adjusted PB Ratio : 15.31 (As of Jun. 03, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Summit Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-06-03), Summit Therapeutics's current share price is MXN425.32. Summit Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was MXN27.78. Summit Therapeutics's Cyclically Adjusted PB Ratio for today is 15.31.

The historical rank and industry rank for Summit Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

MEX:SMMT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.47   Med: 1.46   Max: 19.01
Current: 14.4

During the past years, Summit Therapeutics's highest Cyclically Adjusted PB Ratio was 19.01. The lowest was 0.47. And the median was 1.46.

MEX:SMMT's Cyclically Adjusted PB Ratio is ranked worse than
92.56% of 672 companies
in the Biotechnology industry
Industry Median: 1.475 vs MEX:SMMT: 14.40

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Summit Therapeutics's adjusted book value per share data for the three months ended in Mar. 2025 was MXN9.499. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN27.78 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Summit Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Summit Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Cyclically Adjusted PB Ratio Chart

Summit Therapeutics Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.04 1.75 2.54 1.64 13.54

Summit Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.65 5.07 15.42 13.54 15.26

Competitive Comparison of Summit Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Summit Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Summit Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Summit Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Summit Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=425.32/27.78
=15.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Summit Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Summit Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=9.499/134.9266*134.9266
=9.499

Current CPI (Mar. 2025) = 134.9266.

Summit Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201504 65.905 99.824 89.081
201507 61.769 100.691 82.771
201510 53.911 100.346 72.489
201601 34.023 99.957 45.926
201604 33.368 100.947 44.600
201607 21.306 101.524 28.316
201610 2.021 101.988 2.674
201701 -7.355 102.456 -9.686
201704 -15.776 103.167 -20.633
201707 6.633 103.278 8.666
201710 28.940 104.070 37.521
201801 -5.647 104.578 -7.286
201804 9.101 105.708 11.617
201807 49.158 106.324 62.382
201810 43.857 106.695 55.462
201901 33.136 106.200 42.099
201904 29.570 107.818 37.005
201907 24.252 108.250 30.229
201910 20.700 108.577 25.724
202003 23.528 108.902 29.151
202006 0.000 108.767 0.000
202009 12.112 109.815 14.882
202012 19.140 109.897 23.499
202103 15.877 111.754 19.169
202106 24.420 114.631 28.743
202109 21.545 115.734 25.118
202112 17.426 117.630 19.988
202203 13.070 121.301 14.538
202206 10.522 125.017 11.356
202209 13.313 125.227 14.344
202212 11.698 125.222 12.605
202303 3.449 127.348 3.654
202306 2.939 128.729 3.081
202309 2.481 129.860 2.578
202312 1.879 129.419 1.959
202403 1.045 131.776 1.070
202406 4.934 132.554 5.022
202409 11.698 133.029 11.865
202412 10.991 133.157 11.137
202503 9.499 134.927 9.499

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Summit Therapeutics  (MEX:SMMT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Summit Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Summit Therapeutics Business Description

Traded in Other Exchanges
Address
601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.